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leads	 to	 relatively	 low-risk	 transplants	 for	highly	 sensitized	patients	with	 rejection	
rates	similar	to	those	of	nonimmunized	individuals.









match-negative	 donors.	 The	 Eurotransplant	 Acceptable	 Mismatch	
program	was	established	almost	30	years	ago	with	the	aim	to	provide	
a	chance	for	highly	sensitized	patients	to	be	transplanted,	which	has	
resulted in >1500 transplants.3	The	program	is	based	on	the	positive	
identification	of	HLA	antigens	to	which	the	patient	has	not	made	any	
antibodies by using extensive laboratory testing.4	 Acceptable	 an-
tigens	are	added	 to	 the	HLA	phenotype	of	 the	patient,	 creating	an	
“extended”	HLA	phenotype,	which	is	used	for	allocation.5	Any	avail-






































of	 receiving	 a	 kidney	 through	 the	AM	program	 of	 <0.1%	 (based	
on	 immunological	 grounds),	minimal	HLA	matching	was	 reduced	
to	1	HLA-DR	match	with	 the	patient	on	 the	broad	antigen	 level.	
Furthermore,	whereas	regular	allocation	through	ETKAS	is	based	




includes	 all	 renal	 transplants	 performed	 in	 the	 Netherlands	 be-
tween	 January	 1995	 and	 December	 2005	 with	 available	 clinical	
follow-up.9	 All	 transplants	 required	 a	 negative	 CDC	 crossmatch	
using	both	peak	and	current	sera.	A	detailed	description	of	the	co-
hort	 has	 been	 published	 previously.10	 Clinical	 data	were	 obtained	
from	 the	Dutch	Organ	Transplant	Registry.	Rejection	was	defined	
as	 the	presence	of	biopsy-proved	acute	 rejection	 (without	 further	
classification)	or	any	treatment	for	acute	rejection	when	no	biopsy	
was	 performed.	 Patients	 transplanted	 through	 regular	 allocation	
(ETKAS)	were	grouped	according	to	the	level	of	sensitization	(0%	to	
5%	peak	PRA:	nonsensitized;	6%	to	85%	peak	PRA:	intermediately	
sensitized;	 and	 >85%	 peak	 PRA:	 highly	 sensitized),	 as	 defined	 by	
CDC	assays.	Patients	included	on	the	AM	waitlist	remained	on	the	
ETKAS	waitlist	 as	well,	 and	 those	who	were	actually	 transplanted	
through	ETKAS	(and	thus	received	an	organ	based	on	the	absence	
of	unacceptable	antigens	only)	are	included	in	the	>85%	PRA	ETKAS	





0‐5% PRA 6‐85% PRA >85% PRA
N = 1991 N = 968 N = 121 N = 113 N = 3193
Sex	of	recipient Female 34.3% 48.5% 59.5% 68.1% 1301 <.001
Male 65.7% 51.5% 40.5% 31.9% 1892
Sex	of	donor Female 48.8% 44.6% 47.9% 43.4% 1510 .156
Male 51.2% 55.4% 52.1% 56.6% 1683
Age	of	recipient	(y) ≤50 46.3% 53.9% 64.5% 64.6% 1594 <.001
>50 53.7% 46.1% 35.5% 35.4% 1599
Age	of	donor	(y) ≤50 57.3% 63.1% 61.2% 58.4% 1891 .023
>50 42.7% 36.9% 38.8% 41.6% 1302
Donor type HB 66.5% 73.9% 90.1% 99.1% 2260 <.001
NHB 33.5% 26.1% 9.9% 0.9% 933
Repeat transplant No 93.4% 71.6% 40.5% 46.0% 2654 <.001




1, 2, 3 82.5% 81.7% 84.3% 90.3% 2637 .144
4,	5,	6 17.5% 18.3% 15.7% 9.7% 556
Transplant period 1996-2000 45.0% 57.5% 63.6% 42.5% 1577 <.001





65.8% 63.2% 64.7% 42.6% 1497 .002
Pred/tacro/MMF	±	
IL2RA
34.2% 36.8% 35.3% 57.4% 828
Initial graft functionb  Direct 64.5% 69.3% 67.3% 79.6% 1991 .002
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group.	The	study	design	is	schematically	depicted	in	Figure	S1,	and	
patient	characteristics	are	depicted	in	Table	1.	All	patients	provided	









study as described previously.10
2.4 | Data handling
Groupings	 of	 quantitative	 variables	 were	 based	 on	 the	 following	
strategies:	 transplant	period	was	divided	 into	2	equal	periods,	and	
recipient	 and	 donor	 ages	 of	 50	 years	were	 used	 for	 stratification	











significance	was	 determined	 by	 using	 the	 log-rank	 test,	 corrected	
for	 multiple	 comparisons	 (Bonferroni	 method),	 where	 applicable.	
Inclusion	criterion	 for	 the	multivariate	analysis	was	a	univariate	P-
value	of	<.1.	Multivariate	Cox	regression	analysis	was	performed	to	
determine	 independent	 effects	 on	 6-month	 cumulative	 rejection	
incidence. P-values	were	2-tailed,	and	those	<.05	were	considered	
statistically	 significant.	 SPSS	 version	 23	 (IBM,	 Armonk,	 NY)	 and	
GraphPad	 Prism,	 version	 7.04	 (GraphPad	 Software,	 La	 Jolla,	 CA)	
were	used.
3  | RESULTS
3.1 | Allocation based on acceptable mismatches 









sensitized	patients	 transplanted	 through	 the	AM	program	showed	

































0-5% PRA (n= 1991)
6-85% PRA (n= 968)
>85% PRA (n= 121)
Number of
transplants
0-5% PRA    1991      1403  1330      1306 1296
6-85% PRA    968 635 601 588 584
>85% PRA    121     61  54     54 53
AM 113     84  80     78 78



























0-5% PRA    1296       1146 1055    955
6-85% PRA    584 518 478    442
>85% PRA 53     4 9 34
AM 78     7
7 3
3 65 60
0-5% PRA (n= 1296)
6-85% PRA (n= 584)
>85% PRA (n= 53)
AM (n= 78)
BA
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HR 95% CI P HR 95% CI P HR 95% CI P
Sex	of	recipient
Female	(ref)             
Male 0.797 0.489 1.300 .364         
Sex	of	donor
Female	(ref)             
Male 0.949 0.599 1.504 .824         
Age	of	recipient	(y)
≤50	(ref)             
>50 0.819 0.502 1.334 .422         
Age	of	donor	(y)
≤50	(ref)             
>50 1.240 0.781 1.969 .362         
Donor type
HB	(ref)             
NHB 1.176 0.429 4.224 .752         
Repeat transplant
No	(ref)             
Yes 0.786 0.497 1.245 .305         
HLA-A,	-B,	-DR	mismatch	(broad	antigen	level)
1,	2,	3	(ref)             
4,	5,	6 1.353 0.712 2.570 .356         
Luminex	defined	DSA
No	(ref)             
HLA	class	I 1.292 0.734 2.276 .374         
HLA	class	II 0.691 0.240 1.991 .493         
HLA	class	I	and	class	II 1.420 0.612 3.296 .415         
Transplant period
1996-2000	(ref)             




            
Pred/tacro/MMF	±	IL2RA 0.581 0.306 1.104 .097 0.665 0.345 1.282 .223     
Initial graft function
Direct	(ref)             
Delayed 1.941 1.190 3.167 .008     1.925 1.163 3.187 .011
Tx	through	AM	program
No	(ref)             








sensitized	 counterparts	 transplanted	 through	 regular	 allocation,	
AM	 patients	 experienced	 a	 significantly	 lower	 rejection	 incidence	
(P = .004,	 Figure	1A).	 To	determine	 the	effect	 of	 the	different	 al-
location	 schemes	on	 rejection	 rates	 later	 after	 transplant,	we	also	
analyzed	the	cumulative	rejection	incidence	between	6	months	and	
5	years	and	observed	no	differences	in	this	later	period	(Figure	1B).
We	 next	 performed	 univariate	 Cox	 regression	 analysis	 on	 all	
highly	 sensitized	 patients	 (n	 =	 234)	with	 variables	 that	 potentially	
affect	the	rejection	incidence	(Table	2).	The	variables	of	sex	and	age	
of	 the	 recipient	and	 the	donor,	donor	 type,	 first	 transplant	versus	
repeat	 transplant,	 HLA	 mismatch	 grade,	 transplant	 period,	 initial	
immunosuppression, and presence of single antigen bead–detected 
DSAs	of	 class	 I,	 class	 II,	or	both	class	 I	 and	class	 II	did	not	 signifi-
cantly	affect	the	cumulative	6-month	rejection	incidence.	The	only	
variables	that	affected	the	incidence	of	rejection	were	delayed	graft	
function	 (hazard	ratio	 [HR]	1.94,	95%	confidence	 interval	 [CI]	1.19	
to 3.17; P = .008)	and	 receiving	a	 transplant	 through	 the	AM	pro-
gram	(HR	0.47,	95%	CI	0.29	to	0.76;	P = .002).	The	variables	of	trans-
plant period, initial immunosuppression, initial graft function, and 
transplant	through	the	AM	program	were	selected	for	subsequent	




main immunosuppression categories. To exclude an interaction be-
tween	 initial	 immunosuppression	 and	 transplant	 through	 the	 AM	
program,	we	first	analyzed	these	variables	in	a	separate	multivariate	
analysis and observed only a minimal effect of initial immunosup-
pression	 on	 the	 variable	 transplant	 through	 the	 AM	 program	 (HR	
changes	from	0.47	to	0.54,	Table	2).	Subsequent	multivariate	anal-
yses on transplant period, initial immunosuppression, initial graft 
function,	and	transplant	through	the	AM	program	showed	that	only	
delayed	graft	function	(HR	1.93,	95%	CI	1.16	to	3.19;	P = .011)	and	
receiving	 a	 transplant	 through	 the	AM	program	 (HR	0.57,	 95%	CI	
0.34	to	0.95;	P = .029)	were	independently	associated	with	6-month	
cumulative	rejection	incidence	(Table	2).
3.2 | Minimal match criteria do not result in lower 
rejection rates in AM patients
It	 has	 previously	 been	 shown	 that	 AM	patients	 transplanted	with	
a	minimal	match	 level	of	2	HLA-DR	antigens	or	of	1	HLA-DR	and	







mentioned	minimal	match	 level,	 but	 a	minimum	match	 of	 1	HLA-
DR	on	the	broad	antigen	level,	significantly	increased	the	6-month	

































2 DR or 1 DR+≥1 B match (n= 18)
Number of
transplants
2 DR or 1 DR+≥ 1 B   18        5    4    4 4
Other   103       62 56        56 56



























2 DR or 1 DR+≥1 B match (n= 25)
  25 20 20        20 20
  107       80 76        73         73
>85% PRA ETKAS AM programBA
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location	 is	 associated	 with	 an	 elevated	 risk	 for	 graft	 rejection.14-16 
The	current	study	confirms	these	data,	with	the	cumulative	rejection	
incidence	for	highly	sensitized	patients	transplanted	through	ETKAS	


















































Currently,	 acceptable	 antigens	 for	 HLA-DQA,	 HLA-DPA,	 and	
HLA-DPB	 are	 not	 yet	 accounted	 for	 in	 the	 AM	 program,	 which	
leaves	 the	 possibility	 that	 rejection	 rates	 for	 AM	 patients	 could	
be	 even	 lower	 when	 these	 loci	 are	 also	 taken	 into	 consideration.	
Indeed,	 HLA-DQ	 seems	 to	 be	 the	 dominant	 target	 for	 HLA	 anti-
bodies after transplant.21,22	Future	analyses	 should	show	whether	
extension	of	acceptable	mismatches	to	these	additional	loci	will	in-






within	 the	whole	of	Eurotransplant	 is	 desirable,	we	expect	 similar	
results	to	the	current	study.










long-term	 graft	 survival	 to	 have	 a	 true	 impact	 on	 the	 waitlist	 of	













materials/analysis	 tools.	 Drs	 Hilbrands,	 MCB,	 van	 Reekum,	 van	
Zuilen,	Verhaar,	Seelen,	Sanders,	van	Duijnhoven,	Gelen,	Christiaans,	
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